A Zebrafish Thrombosis Model for Assessing Antithrombotic Drugs - PubMed (original) (raw)

A Zebrafish Thrombosis Model for Assessing Antithrombotic Drugs

Xiao-Yu Zhu et al. Zebrafish. 2016 Aug.

Abstract

Thrombosis is a leading cause of death and the development of effective and safe therapeutic agents for thrombotic diseases has been proven challenging. In this study, taking advantage of the transparency of larval zebrafish, we developed a larval zebrafish thrombosis model for drug screening and efficacy assessment. Zebrafish at 2 dpf (days post fertilization) were treated with phenylhydrazine (PHZ) and a testing drug for 24 h. Tested drugs were administered into the zebrafish either by direct soaking or circulation microinjection. Antithrombotic efficacy was quantitatively evaluated based on our previously patented technology characterized as an image analysis of the heart red blood cells stained with O-dianisidine staining. Zebrafish at 2 dpf treated with PHZ at a concentration of 1.5 μM for a time period of 24 h were determined as the optimum conditions for the zebrafish thrombosis model development. Induced thrombosis in zebrafish was visually confirmed under a dissecting stereomicroscope and quantified by the image assay. All 6 human antithrombotic drugs (aspirin, clopidogrel, diltiazem hydrochloride injection, xuanshuantong injection, salvianolate injection, and astragalus injection) showed significant preventive and therapeutic effects on zebrafish thrombosis (p < 0.05, p < 0.01, & p < 0.001) in this zebrafish thrombosis model. The larval zebrafish thrombosis model developed and validated in this study could be used for in vivo thrombosis studies and for rapid screening and efficacy assessment of antithrombotic drugs.

PubMed Disclaimer

Cited by

Generation and Application of the Zebrafish heg1 Mutant as a Cardiovascular Disease Model.
Lu S, Hu M, Wang Z, Liu H, Kou Y, Lyu Z, Tian J. Lu S, et al. Biomolecules. 2020 Nov 12;10(11):1542. doi: 10.3390/biom10111542. Biomolecules. 2020. PMID: 33198188 Free PMC article.
Animal models for thrombotic thrombocytopenic purpura: a narrative review.
Zheng L, Zheng XL. Zheng L, et al. Ann Blood. 2023 Sep 30;8:23. doi: 10.21037/aob-22-18. Epub 2022 Nov 16. Ann Blood. 2023. PMID: 39148951 Free PMC article.
Identifying of Anti-Thrombin Active Components From Curcumae Rhizoma by Affinity-Ultrafiltration Coupled With UPLC-Q-Exactive Orbitrap/MS.
Lan Z, Zhang Y, Sun Y, Wang L, Huang Y, Cao H, Wang S, Meng J. Lan Z, et al. Front Pharmacol. 2021 Dec 10;12:769021. doi: 10.3389/fphar.2021.769021. eCollection 2021. Front Pharmacol. 2021. PMID: 34955839 Free PMC article.
Discovering a Multi-Component Combination against Vascular Dementia from Danshen-Honghua Herbal Pair by Spectrum-Effect Relationship Analysis.
Zhang P, He S, Wu S, Li Y, Wang H, Yan C, Yang H, Li P. Zhang P, et al. Pharmaceuticals (Basel). 2022 Aug 29;15(9):1073. doi: 10.3390/ph15091073. Pharmaceuticals (Basel). 2022. PMID: 36145294 Free PMC article.
Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models.
Chen M, Liu C, Dai M, Wang Q, Li C, Hung W. Chen M, et al. PLoS One. 2022 Feb 16;17(2):e0262942. doi: 10.1371/journal.pone.0262942. eCollection 2022. PLoS One. 2022. PMID: 35171916 Free PMC article.

A Zebrafish Thrombosis Model for Assessing Antithrombotic Drugs - PubMed (original) (raw)